Navigation Links
Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
Date:2/27/2008

PITTSBURGH, Feb. 27 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced today that it and Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc. (NYSE: FRX) have amended their January 2006 agreement to commercialize, develop and distribute the novel beta blocker Bystolic(TM) (nebivolol), which is currently approved in the United States for the treatment of hypertension. The companies have agreed that Forest will assume Mylan's commercial rights for Bystolic in the U.S. and Canada including, but not limited to, the elimination of Mylan's option to co-promote the product. Forest will be responsible for all future Bystolic development expenses as well as all sales and marketing expenses for the product.

Under the terms of this amendment, Forest Laboratories Holdings, Ltd. (Ireland) will make a one-time cash payment of $370 million to Mylan. Forest will continue to pay Mylan its contractual royalties for three years, through calendar 2010.

Robert J. Coury, Vice Chairman and CEO of Mylan, commented: "We are very proud of the role Mylan has played to date in Bystolic's development and commercialization in the U.S. and believe that today's agreement with Forest is evidence of the value we have created through this product. Today's announcement is just one of the many initiatives we have announced to enhance our strategic focus and ensure we are ideally positioned to maximize the significant opportunities of our world leading generics assets."

About Bystolic

'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
2. Mylan to Host Investor Day on October 3, 2007
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... forefront of diagnostics today, with imaging techniques like ... and NMR (nuclear magnetic resonance) increasing steeply over ... image resolution and quality still limit these techniques ... solution is hyperpolarization, which involves injecting the patient ... following the distribution and fate of specific molecules ...
(Date:9/29/2014)... VIRGINIA BEACH, Va. , Sept. 29, 2014 ... scientists from the fields of cartilage repair, regeneration, ... as attendees from around the world gathered to ... 2014 LifeNet Health Institute of Regenerative Medicine symposium, ... Future Direction . Topics included Orthopedic Biosurgery, Minced ...
(Date:9/29/2014)... , Sept. 29, 2014 /PRNewswire/ - Portage Biotech Inc. ... PBT.U), is pleased to announce that its three Promissory ... Portage, who advanced $ 100,000 each in July 2014 ... their Notes and related Coupons converted into 3,500,001 restricted ... carried 5% coupon. Both the Note and the coupon ...
(Date:9/29/2014)... lithium batteries are efficient but involve a range ... alfalfa (lucerne seed) and pine resin and a ... up with a highly interesting alternative. Their study ... ChemSusChem . , ,We think our discovery ... solutions for the batteries of the future, says ...
Breaking Biology Technology:A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Smart, eco-friendly new battery to solve problems 2
... , , SAN FRANCISCO, Aug. 4 Nile ... the development of novel therapeutics for heart failure patients, today announced ... of its lead product, CD-NP, for the treatment of acute heart ... study is designed to provide additional information on the safety and ...
... /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) ... Hausman, M.D., as Vice President, Clinical Development at Oncothyreon. ... planning and implementing the clinical development program for the ... is an experienced oncologist who brings an extensive background ...
... , PALO ALTO, Calif., August ... antiviral therapies, announced today that it has licensed the exclusive ... Stanford University. This technology, discovered in the lab of Stanford ... focused on a variety of novel targets, including key features ...
Cached Biology Technology:Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure 2Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure 3Oncothyreon appoints Diana Hausman as Vice President of Clinical Development 2Oncothyreon appoints Diana Hausman as Vice President of Clinical Development 3Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University 2
(Date:9/29/2014)... Energy Joint Genome Institute (DOE JGI), a DOE ... 32 new projects have been selected for the ... lakes to Caribbean waters, and from plant root ... in forested watersheds, the CSP 2015 projects portfolio ... be extracted. , "These projects catalyze JGI,s ...
(Date:9/29/2014)... who lived 2,330 years ago in the southernmost tip of ... when his DNA profile is one of the ,earliest diverged, ... region where modern humans are believed to have originated roughly ... ,mitochondrial DNA, was sequenced to provide clues to early modern ... that we all come from Africa, and helps us map ...
(Date:9/29/2014)... Ill. Scientists have discovered a previously unknown ... grow and, in the case of estrogen-positive breast ... work reveals new targets for breast cancer therapy ... the most aggressive treatment. , The University of ... Oncogene . , Estrogen pre-activates the unfolded-protein ...
Breaking Biology News(10 mins):2015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9Ancient human genome from southern Africa throws light on our origins 2Ancient human genome from southern Africa throws light on our origins 3Scientists discover a new role for estrogen in the pathology of breast cancer 2
... Hopkins researchers have created a synthetic protein that, when activated ... body where cancer, arthritis and other serious medical disorders can ... type of diagnostic imaging technology and may someday serve as ... where signs of disease have been found. In a study ...
... mood for food can be changed by a restaurant,s choice ... calorie intake, according to a new study., "When we did ... music and lighting led diners to eat 175 fewer calories ... Wansink, professor of marketing and director of Cornell University,s Food ...
... FARMINGTON, Conn., Aug. 29, 2012 /PRNewswire-iReach/ -- The biobanking market ... new drug and treatment development for specific diseases. The ... and is projected to increase by 30% between 2010 and ... Private sector biobanks will experience the greatest increase with growth ...
Cached Biology News:Collagen-seeking synthetic protein could lead doctors to tumor locations 2Collagen-seeking synthetic protein could lead doctors to tumor locations 3Global Biobanking Market Projected to Increase by 30% to Reach $183 Billion by 2015 2Global Biobanking Market Projected to Increase by 30% to Reach $183 Billion by 2015 3
...
One-step, microplate or cuvet, colorimetric, detection range 0.3 g/dL to 5 g/dL. Procedure: 5 min....
Donor Goat Serum...
The Varian 4000 GC/MS system offers three easily switchable ionization configurations: internal ionization (II), external ionization (EI) or hybrid chemical ionization (CI)...
Biology Products: